Breast cancer subtypes and response to docetaxel in node-positive breast cancer: Use of an immunohistochemical definition in the BCIRG 001 trial

Public Deposited
Analytics

Downloadable Content

Download PDF
Request Version for Screen Reader
Creator
  • Hugh, Judith
  • Hanson, John
  • Cheang, Maggie Chon U.
  • Nielsen, Torsten O.
  • Perou, Charles
  • Dumontet, Charles
  • Reed, John
  • Krajewska, Maryla
  • Treilleux, Isabelle
  • Rupin, Mattheiu
  • Magherini, Emmanuelle
  • Mackey, John
  • Martin, Miguel
  • Vogel, Charles
Abstract
  • Purpose To investigate the prognostic and predictive significance of subtyping node-positive early breast cancer by immunohistochemistry in a clinical trial of a docetaxel-containing regimen. Methods Pathologic data from a central laboratory were available for 1,350 patients (91%) from the BCIRG 001 trial of docetaxel, doxorubicin, and cyclophosphamide (TAC) versus fluorouracil, doxorubicin, and cyclophosphamide (FAC) for operable node-positive breast cancer. Patients were classified by tumor characteristics as (1) triple negative (estrogen receptor [ER]–negative, progesterone receptor [PR]–negative, HER2/neu [HER2]–negative), (2) HER2 (HER2-positive, ER-negative, PR-negative), (3) luminal B (ER-positive and/or PR-positive and either HER2-positive and/or Ki67high), and (4) luminal A (ER-positive and/or PR-positive and not HER2-positive or Ki67high), and assessed for prognostic significance and response to adjuvant chemotherapy. Results Patients were subdivided into triple negative (14.5%), HER2 (8.5%), luminal B (61.1%), and luminal A (15.9%). Three-year disease-free survival (DFS) rates (P values with luminal B as referent) were 67% (P < .0001), 68% (P = .0008), 82% (referent luminal B), and 91% (P = .0027), respectively, with hazard ratios of 2.22, 2.12, and 0.46. Improved 3-year DFS with TAC was found in the luminal B group (P = .025) and a combined ER-positive/HER2-negative group treated with tamoxifen (P = .041), with a marginal trend in the triple negatives (P = .051) and HER2 (P = .068) subtypes. No DFS advantage was seen in the luminal A population. Conclusion A simple immunopanel can divide breast cancers into biologic subtypes with strong prognostic effects. TAC significantly complements endocrine therapy in patients with luminal B subtype and, in the absence of targeted therapy, is effective in the triple-negative population.
Date of publication
Keyword
DOI
Identifier
Related resource URL
Resource type
  • Article
Rights statement
  • In Copyright
Journal title
  • Journal of Clinical Oncology
Journal volume
  • 27
Journal issue
  • 8
Language
  • English
Version
  • Publisher

Relations

Parents:

This work has no parents.

Items

Thumbnail Title Date Uploaded Visibility Actions
file details Breast Cancer Subtypes and Response to Docetaxel in Node-Positive Breast Cancer Use of an Immunohistochemical Definition in the BCIRG 001 Trial (2).pdf 2019-05-03 Public Download
file details Breast cancer subtypes and response to docetaxel in node-positive breast cancer Use of an immunohistochemical definition in the BCIRG 001 trial.pdf 2019-05-03 Public Download